Preliminary data from a phase 1 trial of CAR T-cell therapy shows therapeutic responses in relapsed/refractory multiple myeloma patients.
After in vitro testing of azacitidine showed positive results, Cleveland Clinic researchers conducted one of the first trials to study azacitidine in relapsed or refractory multiple myeloma patients.
Jianjun Zhao, MD, PhD, receives a two-year, $200,000 grant to study how the MALAT1 gene may protect against multiple myeloma. He also will look for targeted ways to deliver a potential MALAT1 inhibitor.
Relapse is inevitable for almost all patients with multiple myeloma. A new drug combination extends progression-free survival in a significant way.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Using an innovative screening assay and an enlightened approach to drug discovery, a Cleveland Clinic-led team of researchers has identified CCF642 — a small-molecule compound that represents a new class of anticancer agents. CCF642 has broad anti-myeloma activity in vivo, prolonging survival in a mouse model of multiple myeloma comparable to the survival extension achieved by the FDA-approved first-line therapeutic agent bortezomib.
Most patients with multiple myeloma will suffer a vertebral fracture. Two new papers radiographically characterize these fractures’ progression in this population for the first time. Here are the takeaways.
Cleveland Clinic researchers have designed a new approach to drug therapy for multiple myeloma patients which, in pilot testing, achieved uniform disease control and reduced adverse events and costs.
Promising Cleveland Clinic studies are open to evaluate new agents and regimens for multiple myeloma and amyloidosis. Multidisciplinary support is offered for patients with complex issues.